Back to top

Analyst Blog

Riding on a strong growth momentum ahead of its second-quarter earnings release, the shares of Santarus, Inc. closed at $25.57 on Jul 12, 2013. Just last week, Santarus had hit a 52-week high of $24.07 and it touched $25.71 on Friday’s trading session, representing an upside of 6.8%.

The Zacks Rank #2 (Buy) specialty biopharmaceutical company has consistently delivered positive earnings surprises for the last three quarters. In the first quarter of 2013, the company posted a surprise of 108.33%.

Santarus reported revenues of almost $80 million in the first quarter of 2013. Going forward, performance should be driven by Uceris (mild-to-moderate ulcerative colitis), Zegerid (heartburn and other symptoms of gastroesophageal reflux disease) and Glumetza (type II diabetes).

Uceris, which generated sales of $6.6 million in first quarter of 2013, should continue growing on a sequential basis over the rest of 2013. The Zegerid re-launch should aid revenues as well. Glumetza, targeting the lucrative diabetes market, is expected to witness sales growth from the second quarter of 2013.

Santarus also possesses a strong pipeline consisting of interesting candidates like Ruconest for hereditary angioedema (HAE). The US Food and Drug Administration (FDA) is reviewing the marketing application of Ruconest for the acute treatment of HAE and will render a decision by Apr 2014. Santarus also plans to develop the candidate for the prophylaxis treatment of HAE and acute pancreatitis.

On a price-to-sales basis, Santarus is trading at 7.7x, reflecting a huge premium of 133.3% compared with the peer group average of 3.3x. On a price-to-book basis, the stock is also trading at a premium to the peer group average. However, given the company’s strong fundamentals, the premium valuation is justified.

At present, companies like Jazz Pharmaceuticals (JAZZ - Analyst Report), Cadence Pharmaceuticals Inc. and NPS Pharmaceuticals, Inc. (NPSP - Analyst Report) look more attractive with a Zacks Rank #1 (Strong Buy).

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
UNITED THER… UTHR 117.83 +28.51%
TRIQUINT SE… TQNT 20.67 +6.52%
RF MICRO DE… RFMD 12.47 +6.04%
VASCO DATA… VDSI 14.77 +4.68%
BANCO DO BR… BDORY 15.53 +3.95%